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Abstract
Bayesian inference has commonly been performed on nonlinear mixed effects mod-
els. However, there is a lack of research into performing Bayesian optimal design for
nonlinear mixed effects models, especially those that require searches to be performed
over several design variables. This is likely due to the fact that it is much more compu-
tationally intensive to perform optimal experimental design for nonlinear mixed effects
models than it is to perform inference in the Bayesian framework. Fully Bayesian ex-
perimental designs for nonlinear mixed effects models are presented, which involve
the use of simulation-based optimal design methods to search over both continuous
and discrete design spaces. The design problem is to determine the optimal number of
subjects and samples per subject, as well as the (near) optimal urine sampling times
for a population pharmacokinetic study in horses, so that the population pharmacoki-
netic parameters can be precisely estimated, subject to cost constraints. The optimal
sampling strategies, in terms of the number of subjects and the number of samples per
subject, were found to be substantially different between the examples considered in
this work, which highlights the fact that the designs are rather problem-dependent and
can be addressed using the methods presented.
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1. Introduction
1.1. Background
Nonlinear mixed effects models (NLMEMs) are commonly used to model data in
which heterogeneity exists between study subjects. For example, population pharma-
cokinetic (PK) studies investigate the disposition of a drug within a large sample of
subjects. For an extensive overview of NLMEMs, as well as general theoretical de-
velopments and examples, see Racine-Poon (1985) and Davidian (2009). NLMEMs
require the mean value of the population parameters to be estimated, as well as their
inter-individual variability. The experimental design, which is usually under the con-
trol of the investigator, is responsible for determining the quality of the analyses of the
data modelled by the NLMEM. These models, which are also known as the population
approach, can allow for a sparse sampling design where only a few data points are
available per individual, but a large number of individuals are included in the study.
This is useful for studies in which the experimenters are interested in collecting in-
formative data to obtain precise parameter estimates, but the number of samples per
subject is limited due to ethical, physiological, time or cost constraints.
As the use of NLMEMs for modelling data from population studies has increased,
so has the importance of optimally designing population studies so that accurate and
precise estimates of the population parameters can be obtained (e.g., Mentre´ et al.
(1997); Retout and Mentre´ (2003); Han and Chaloner (2004)). In this paper we are
interested in (static) experimental designs that are optimal for the estimation of the
population parameters in NLMEMs.
It is well known that the sampling times in a PK study can have a large impact on
the precision and bias of parameter estimates (D’Argenio (1981)). However, there is
contention in the literature as to whether it is better to sparsely sample a larger num-
ber of individuals, or to heavily sample a smaller number of individuals in population
studies. Sheiner and Beal (1983), Hashimoto and Sheiner (1991), and Jonsson et al.
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(1996) evaluate the effect of altering the number of subjects, and the number and timing
of blood samples in PK studies on the precision and bias of the estimated parameter
values. Sheiner and Beal (1983), and Hashimoto and Sheiner (1991) recommend that
designs which use more study subjects, even if the majority are sparsely sampled, are
preferable over designs which use more sampling times on fewer individuals. Con-
versely, Jonsson et al. (1996) recommend increasing the number of samples per sub-
ject, even if the total number of study subjects is small, so that the parameter estimates
are unbiased and precise. However, these studies only investigate the use of a small
number of sampling times (up to three sampling times), which were often fixed in their
values and did not optimise a utility function over the design space.
1.2. Bayesian Hierarchical Model Framework
In the Bayesian framework, mixed effects models are commonly constructed using
hierarchical models. These models account for the different levels of variability within
and between populations. The observable outcomes are modelled conditionally on
certain parameters, which are themselves assigned a probability distribution in terms
of other parameters which are known as hyperparameters.
Here we consider NLMEMs where the h-th observation of individual i, Yi,h, is given
by:
Yi,h = f (φi,di,h) + i,h,
where f (·) is a nonlinear mean function (which is the same for all individuals); φi is a
random (or subject-specific) effect for individual i, which is treated as a latent variable
in a Bayesian analysis; di,h is the experimental setting; and the errors are independent
and distributed as i,h ∼ N(0, σ2). It is assumed that there are n subjects involved in the
study.
A population distribution is specified for the subject-specific effects φi, i = 1, ..., n:
φi ∼ MVN(φ,Ω),
where φ and Ω are the population mean and variance-covariance matrix respectively.
Here φ is the population parameter or fixed effect. In this work we assumeΩ is known.
Racine-Poon (1985) provides guidance on prior elicitation for unknown Ω. We define
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the unknown quantities as θ = (φ,φ1:n), where φ1:n = (φ1, ...,φn). A log normal or
inverse gamma prior (with shape hyperparameters a0 and b0) may be used for the ob-
servational variance, σ2. Priors for the population parameters may also be specified
as:
φ ∼ MVN(µ,Σ).
where µ is the prior mean for φ and Σ is the prior variance-covariance for φ. In this
work, the values for the hyperparameters µ and Σ are based on historical data.
1.3. Bayesian Optimal Design Theory
Bayesian experimental design has recently gained popularity in the literature and
has many real-world applications. The Bayesian optimal design framework involves
defining a prior distribution for the population parameter φ and a population model
for the subject-specific effects φ1:n; a conditional sampling distribution p(yi|d,φi) for
observing a new set of measurements yi for individual i at the design points d, given
parameter values φi; and a utility function U(d, θ, y) that describes the reward that is
obtained for taking measurements at design points d, and observing the data y (where
y = (y1, ..., yn)), assuming the model parameter values θ are known. In this work, we
assume that measurements are taken at the same design points d for all study subjects.
The optimal Bayesian design, d∗, maximises the expected utility function U(d)
over the design space D with respect to the future data y and model parameter θ:
d∗ = arg max
d∈D
E{U(d, θ, y)}
= arg max
d∈D
∫
Y
∫
Φ
∫
Φ1:n
U(d, θ, y)
n∏
i=1
{
p(yi|d,φi)p(φi|φ)dφi
}
p(φ)dφdy, (1)
where p(yi|d,φi)p(φi|φ) is the complete data likelihood for subject i, p(yi|d,φ) is the
observed data likelihood for subject i, p(φi|φ) is the population distribution for the
random effects and p(φ) is the prior distribution for the fixed effects φ. The random
effects must be integrated out from equation (1).
The applied statistician’s default approach to analysing data in a Bayesian frame-
work is to use uninformative priors. When designing an experiment, it is reasonable
to assume that, generally, there is historical and/or expert opinion available to formu-
late an informative prior (e.g., Clyde et al. (1996); Stroud et al. (2001); Ryan et al.
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(2015)). Therefore, the prior predictive distribution gives ranges of data values that the
experimenter believes to be plausible.
1.4. Likelihood Function Approximation for NLMEMs
Due to the nonlinearity, NLMEMs have no analytical expression for the observed
data likelihood. There is a wealth of literature on approaches for approximating the
observed data likelihood to perform inference for the population parameters φ. These
methods include: first-order approximations (Sheiner and Beal (1983)); first order con-
ditional methods (Lindstrom and Bates (1990)); Gaussian quadrature (e.g., Davidian
and Gallant (1993)); adaptive Gaussian quadrature (e.g., Rabe-Hesketh et al. (2004));
Laplace approximations (e.g., Beal and Sheiner (2002)); Markov chain Monte Carlo
(MCMC) (e.g., Spiegelhalter et al. (1996)); Monte Carlo integration (e.g., Wakefield
(1994)); and importance sampling (Geweke (1989)). From the Bayesian perspective,
the unknowns φ1:n and φ have the same status, i.e., inference for either φ1:n or φ is made
using the posterior distribution. This is not the case for frequentist inference where φ1:n
are random variables and φ is a constant.
1.5. Bayesian Designs for NLMEMs
Classical design criteria often consist of scalar functions of the Fisher information
matrix (FIM), such as the determinant or the trace (e.g., Mentre´ et al. (1997); Retout
and Mentre´ (2003)). Pseudo-Bayesian design criteria also rely on functions of the FIM,
but also average these functions over a “prior” for the model parameters to account for
parameter uncertainty (e.g., Pronzato and Walter (1985)). Once an expression for the
likelihood has been found one can then derive the FIM.
Bayesian design criteria are often based upon the expected gain in Shannon in-
formation from the prior to posterior distribution (also known as ‘mutual informa-
tion’ or the ‘Kullback-Leibler distance’) (e.g., Chaloner and Verdinelli (1995)). Other
commonly-used Bayesian design criteria are based on the spread of the posterior distri-
bution, which may be measured, for example, by the precision or by the entropy (e.g.,
Stroud et al. (2001)). When the posterior distribution is found by simulation, it must
be sampled from for each future data set that is drawn from the prior predictive distri-
bution, and so many thousands of posterior distributions are often required to perform
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Bayesian experimental design. For this reason, fully Bayesian experimental designs
for NLMEMs are largely unexplored.
Han and Chaloner (2004) searched for Bayesian population designs for a HIV dy-
namics study. They did not optimise over a continuous design space, but instead con-
sidered 8 fixed sampling schedules. The posterior predictive variance for two param-
eters was used in the utility function, and MCMC was used to sample the posterior
distribution for each future dataset. Palmer and Mu¨ller (1998) implemented Bayesian
optimal designs for population models for determining the timing of stem cell collec-
tions in cancer patients. The NLMEM parameters were estimated by MCMC simula-
tion and a discrete set of designs was searched over.
Stroud et al. (2001) fitted NLMEMs to existing data relating to the PK of the an-
ticancer agent, paclitaxel, in patients and found (sequential) Bayesian designs for the
subject-specific parameters for the next patient. The design variable was the blood
sampling times and two utility functions were used: the posterior precision of the area
under the curve and the posterior precision of the time above a certain drug concen-
tration. Each of these utility functions also included a cost penalty (which penalised
sampling times that occurred after some pre-specified time) and were estimated using
importance sampling. A Metropolis-Hastings MCMC algorithm (e.g., Mu¨ller (1999))
was used to find the optimal design.
1.6. Contribution and Outline
In this paper, we present static, fully Bayesian designs for population parameters of
NLMEMs, in which we use simulation-based optimal design methods to search over
both continuous and discrete design spaces. We define a ‘continuous design space’ to
be one in which the designs can take on any value in a pre-defined continuous interval,
rather than values from a fixed set of discrete values. Whilst previous studies have
found optimal Bayesian designs for NLMEMs by searching over a finite set of designs
(e.g., Han and Chaloner (2004); Palmer and Mu¨ller (1998)), to our knowledge, no
studies have searched over a continuous design space to find optimal static Bayesian
designs for NLMEMs. This work is motivated by a PK study conducted by McGree
et al. (2012) which models the PK of an acepromazine metabolite in racing horses. Our
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design problem consists of finding the optimal sampling times for the PK study, as well
as the optimal number of subjects to incorporate into the study, and the optimal number
of samples to take per subject. To our knowledge, no previous Bayesian experimental
design studies have addressed all of these issues (over a continuous design space). We
are interested in finding designs that maximise the posterior precision of the population
parameters, subject to cost constraints.
In Section 2 we describe the design methodology used in this work. In Section
3 we obtain some results for a simple example that involves designing for a linear
mixed effects regression model. In Section 4 the PK case study is introduced and our
design methods are applied to the case study in Section 5. The article concludes with a
discussion in Section 6.
2. Bayesian Experimental Design Framework
Equation (1) does not usually have a closed form solution, and so numerical ap-
proximations or simulation methods are used to solve the maximisation and integration
problem. These include: numerical quadrature or Laplace approximations (Brockwell
and Kadane (2003); Ryan et al. (2015)); prior simulation (Mu¨ller (1999)); MCMC
simulation in an augmented probability model (Mu¨ller (1999)); and sequential Monte
Carlo (Amzal et al. (2006)).
In this work, we use the approach implemented by Mu¨ller (1999) to solve equation
(1). This involves the use of MCMC which samples from the target distribution:
h(d, θ, y) ∝ U(d, θ, y)p(θ, y|d),
using a Metropolis-Hastings scheme. h(·) is constructed in such a way that the marginal
distribution h(d) is proportional to the expected utility, U(d). It is assumed that the
utility U(d, θ, y) is non-negative and bounded, and that h(·) is integrable and can be
normalised. The sample of simulated d may be used to provide an estimate of h(d)
and the joint mode of h(d), d∗, corresponds to the optimal design. The Metropolis-
Hastings scheme of Mu¨ller (1999) is described in Algorithm 1 and has been adapted
for designing for NLMEMs.
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Algorithm 1: MCMC algorithm for Bayesian optimal design for NLMEMs
1 Set an initial design d(1).
2 Draw φ ∼ p(φ), φi ∼ p(φi |φ), yi ∼ p(yi |d(1),φi), for i = 1, ..., n individuals.
3 Compute U(1) = U(d(1), θ, y), where y = (y1, ..., yn) and θ = (φ,φ1:n).
4 for j = 1 to iters do
5 Generate a candidate design d˜ from a proposal distribution q(·|d( j)).
6 Generate proposals for the parameters and simulate data:
7 φ˜ ∼ p(φ), φ˜i ∼ p(φi |φ˜), y˜i ∼ p(yi |d˜, φ˜i), for i = 1, ..., n individuals.
8 Compute U˜ = U(d˜, θ˜, y˜), where y˜ = (y˜1, ..., y˜n) and θ˜ = (φ˜, φ˜1:n).
9 Calculate the MH acceptance probability, a = min(1, A) where
A =
U˜ × q(d( j) |d˜)
U( j) × q(d˜|d( j)) .
Here U( j) and d( j) are the current utility and design point values, respectively, and U˜ and d˜ are
the proposed utility and design point values, respectively.
10 Set
(d( j+1),U( j+1)) = (d˜, U˜)
with probability a, and
(d( j+1),U( j+1)) = (d( j),U( j))
with probability 1 − a.
11 endfor
Simulation-based algorithms such as those presented by Mu¨ller (1999) have been
found to have slow convergence for situations where there are a large number (≥ 4) of
design variables (e.g., Stroud et al. (2001); Amzal et al. (2006)). For our PK application
of interest, we are interested in searching for up to 15 sampling times. To ease the com-
putational burden of having to search for a large number of design points, we use an
approach from our previous work (Ryan et al. (2014)) which involves a lower dimen-
sional parameterisation that reduces the design problem to one that involves searching
over two design variables. The lower dimensional parameterisation was used in Line 5
in Algorithm 1. The sampling times for the PK study (Sections 4 and 5) will be gen-
erated from the evenly spaced percentiles of a Beta(a, b) distribution (see Ryan et al.
(2014)), scaled to [0, 48] hours, where a, b > 0. Using this lower dimensional param-
eterisation, the Mu¨ller (1999) algorithm searches over the two design variables (a, b),
and once these optimal values are found, a large number of design points can be gen-
erated from the evenly-spaced percentiles of the Beta(a, b) distribution. However, it
must be noted that the designs generated by this lower dimensional parameterisation
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are not optimal but near optimal, which is a compromise of the computational savings
achieved through these methods. We chose this lower dimensional parameterisation
as we have used it previously for designing for fixed effects PK models (see Ryan
et al. (2014)) and found that it gave fairly flexible designs that could be suitable for PK
studies.
MCMC runs of 10000 iterations were performed and the convergence of the MCMC
algorithm was carefully monitored (through examination of autocorrelation plots, his-
tograms and contour plots of the design variables, and trace plots of the utility functions
over the iterations). To determine the optimal designs, we searched for the multivari-
ate mode of the multivariate normal kernel smoothing density estimates of the design
variables (see Cook et al. (2008); Drovandi and Pettitt (2013)).
2.1. Utility Function Estimation via Importance Sampling
Utility functions are problem-specific and incorporate the aims of an experiment.
Bayesian utility functions make recourse to the posterior distribution p(θ|d, y). How-
ever, for NLMEMs, the posterior does not have a closed form expression and numerical
methods are required for its approximation. We use a similar approach to Stroud et al.
(2001) to generate samples from the posterior distribution, via importance sampling,
for use in the Bayesian utilities.
Importance sampling is a commonly-used approach for approximating target distri-
butions (Geweke (1989)) (in this case, the posterior p(φ1:n,φ|d, y)). It involves choos-
ing an importance distribution g(·) from which it is easy to sample, and then weighting
the samples to account for any differences between the importance and target distribu-
tion. The target and importance distributions should have the same support. Weighted
discrete approximations, {(φ,φ1:n)(l),W (l)}Mpl=1, are produced (where Mp is the number of
values or particles used) from the target distribution, where
w(φ,φ1:n) =
{∏n
i=1 p(yi|d,φi)p(φi|φ)
}
p(φ)
g(φ,φ1:n)
are the importance weights, and W (l) ∝ w((φ,φ1:n)(l)) are the normalised importance
weights,
∑Mp
l=1 W
(l) = 1.
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We use the population distribution (for the random effects) and the prior (for the
fixed effects) as the importance distribution (g(φ,φ1:n) =
{∏n
i=1 p(φi|φ)
}
p(φ)), which
reduces importance weights to the conditional distribution of the data given all the
parameters:
w(φ,φ1:n) =
n∏
i=1
p(yi|d,φi).
This is not to be confused with the observed data likelihood p(y1:n|d,φ) in which the
random effects have been integrated out. Note that the prior p(φ) for the population
parameters is relatively informative for our application as it is based on the results
from the analysis of previous experiments.
To measure the efficiency of importance sampling, the effective sample size (ESS)
is used (Geweke (1989)), where
ESS =
1∑
W (l)2
, 1 ≤ ESS ≤ Mp.
In this work we are only interested in the posterior distribution for the popula-
tion parameters, and so we only use the samples of the subject-specific effects φ1:n to
calculate the importance weights and discard them thereafter. Our method for approxi-
mating the posterior distributions for the population parameters p(φ|d, y) is outlined in
Algorithm 2.
Algorithm 2: Algorithm for approximating p(φ|d, y)
1 Draw {φ(l)}Mpl=1 from p(φ).
2 for i = 1 : n do
3 Draw {φ(l)i }
Mp
l=1 from p(φi |φ(l)), l = 1, ...,Mp
4 endfor
5 {φ(l)}Mpl=1 and {φ(l)1:n}
Mp
l=1 are only drawn once at the beginning of Algorithm 1 (prior to line 1) and are
stored.
6 Weight w(l) =
∏n
i=1 p(y˜i |d˜,φ(l)i ), l = 1, ...,Mp.
7 Normalise w(l) to give W(l), l = 1, ...,Mp.
8 The particle approximation to p(φ|d, y) is given by {φ(l),W(l)}Mpl=1 .
The utility functions can then be estimated using the weighted samples. Algorithm
2 (lines 6 - 8) is used in each iteration of Algorithm 1 (line 8, as well as line 3 at the
beginning of the algorithm) to calculate the utility function. For our applications, we
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will use the determinant of the posterior precision matrix of the population parameters
as the utility function:
U(d, y) = det(prec(φ|d, y)).
For the example considered in Section 5, we set Mp = 100000 as this number of
particles provided reasonably stable (based on the ESS) and precise estimates of the
utility function.
3. Simple Illustrative Example: Linear Mixed Effects Model
We will begin with a simple example, in which we determine the optimal balance
between the number of subjects (n) and the number of samples per subject (nd), as well
as the optimal values for the predictor variable x, under certain conditions. The model
is a linear mixed effects model where the response for the i-th subject is given by:
yi = Xφ + Ziφi +  i, i = 1, ..., n.
The observation vector y is of dimension N×1 (where N = n×nd, i.e., the total number
of observations). X is the design matrix for the fixed effects (of dimension nd × p) and
Zi is the design matrix for the i-th subject (of dimension nd×p). φ consists of the (p×1)
fixed effects, with the prior φ ∼ MVN(0,Σ), where Σ is a known, p × p nonsingular
matrix. φ1:n consists of the (np × 1) random effects, with the model:
(φT1 , ...,φ
T
n ) ∼ MVN(0,Ω),
where Ω is a known, np × np nonsingular matrix. It is assumed that the random
effects are independent. The residuals,  i, are independently distributed with  i ∼
MVN(0, Iσ2), i = 1, ..., n. Here we assume that σ2 is known. It is also assumed that
the observational errors i are independent of the fixed or random effects.
For the linear mixed effects model, Sorenson and Gianola (2002) have derived an
analytical expression for the posterior density of the fixed effects and we will use their
expression (see later, equation (4)) for the posterior precision matrix to construct our
Bayesian utility function. Since the integrals in (1) can be computed analytically, all
that is required is to perform the optimisation to find the design which maximises the
utility function.
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We use a linear regression model of the following form:
yi,h = (φ0 + φi,0) + (φ1 + φi,1)xi,h + (φ2 + φi,2)x2i,h + i,h,
where i = 1, ..., n, h = 1, ..., nd. φT = (φ0, φ1, φ2) and φTi = (φi,0, φi,1, φi,2).
We setΣ = diag(0.4, 0.3, 0.2);Ω = diag(0.2, 0.15, 0.12, 0.2, 0.15, 0.12, ..., 0.2, 0.15, 0.12),
where the number of repeats of the variances (0.2, 0.15, 0.12) for the three random ef-
fects depends on the number of subjects, n; and σ2 = 0.01.
The utility function is the (log) determinant of the posterior precision of the popu-
lation parameters:
U(d, y) = log(det(prec(φ|d, y))). (2)
In addition to precisely estimating the model parameters, our design objectives also
included a cost constraint. Since the posterior precision (of the population parameters)
and cost penalty may not be on the same scale, equation (2) was used to find designs,
subject to a certain fixed maximum cost (Stigler (1971)).
The cost function penalised for the number of subjects in the study, and the total
number of measurements taken in the study:
C = csub · n + csample · n · nd, (3)
where csub is the cost per subject, and was set to $50, and csample is the cost per sample,
and was set to $10. These values were arbitrarily chosen for illustrative purposes.
The cost function was used to determine the different combinations of the number of
subjects and samples per subject that could be included in the study for a fixed total
cost. The (log) determinant of the posterior precision was calculated for each of these
combinations and comparisons were made to see which yielded the highest value of
the utility function.
The expression for the posterior precision of φ is given by:
prec(φ|d, y) = (X′V−1X + Σ−1σ2)σ−2, (4)
where V = ZΩZ′σ−2 + I (Sorenson and Gianola (2002)). Here, Z denotes the design
matrix for the random effects (of dimension N × np). If Ω = 0, then V = I. Note
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that, although the posterior precision does not depend on y here, the posterior mean is
dependent on y. The designs d enter the utility function via the design matrices X and
Z, and therefore only the term X′V−1X in the right hand side of equation (4).
3.1. Results
For a fixed cost of $750, we investigated different combinations of the number
of subjects and the number of samples per subject, to determine the optimal balance
between these two quantities. We also searched over the design space for the predictor
x, whose values were restricted to occur between 0 and 1.
The optimal exact designs were found using the Mu¨ller (1999) algorithm with
10000 iterations. According to classical design theory, the D-optimal design for a
quadratic equation with three unknown fixed effects parameters should have three
support points - one at either end of the design space and one at the centre (e.g.,
Pukelsheim (1993); Tan and Berger (1999)). Therefore, we decided to search over
three predictor design variables, (x1, x2, x3), which were the three support points, and
two weights/integers for an exact design (ω1, ω2), where ω3 = nd − (ω1 + ω2). The
weights determine the number of replicates that are to be placed on each support point.
Therefore, d = (x1, x2, x3, ω1, ω2). We also searched over 4 predictor design variables,
but found that one of these design points was a replicate of one of the three support
points.
Since an analytical expression of the utility function, U(d), was available, the mode
could easily be estimated by choosing the sample with the highest U(d) value. To
simplify matters, it was assumed that all subjects had the same number of observations
at the same values of the predictor variable x. The results are summarised in Table 1.
From Table 1 it can be seen that the optimal support points for the model occur
at the middle of the design space (0.5), and at either end (0 and 1). This is similar to
results obtained in the classical design literature (e.g., Pukelsheim (1993)). Preference
for the replicates was given to the centre (0.5) of the design space, followed by the start
of the design space (0).
It can also be determined from Table 1 that, for this application of interest, it is
preferable to take a smaller number of samples from a larger number of individuals
13
No. Sub-
jects
No. samples per
subject
Total no.
samples
Optimal exact design for x†, ξ Utility function value
U(d)
9 3 27 ξ =
{
0 0.5 1
1 1 1
}
15.55
8 4 32 ξ =
{
0 0.5 1
1 2 1
}
15.47
7 5 35 ξ =
{
0 0.5 1
2 2 1
}
15.26
6 7 42 ξ =
{
0 0.5 1
2 3 2
}
14.77
5 10 50 ξ =
{
0 0.5 1
3 4 3
}
14.72
4 13 52 ξ =
{
0 0.5 1
4 6 3
}
14.27
Table 1: Optimal designs and utility function values for different combinations of the number of subjects and
the number of samples per subject for a fixed cost of $750. †Note that the weights for the exact design (row
2 of ξ) correspond to the number of replicates that are to be taken on each support point (row 1 of ξ) for 1
study subject. The sum of the weights is equal to the number of samples that are to be taken per subject.
(rather than heavily sample a smaller number of individuals). This is in agreement with
Diggle et al. (1994) who note that for a uniform correlation structure (of the errors),
the addition of one repeated measure within a subject conveys less information on the
fixed effects than the addition of an independent measure of a new study subject.
Prior Sensitivity
We are now interested in investigating the effect of the prior distribution for the
fixed effects and the model for the random effects on the optimal number of subjects
and samples per subject. We will begin by varying the prior for the fixed effects φ ∼
N(0, cΣ), where we will use the values c = 0.1, 1, 2, 10, 100. As c → ∞, we would
obtain the same results as in the frequentist paradigm. The population model for the
random effects is the same as above. The same combinations of the number of subjects
and samples per subject were used as in Table 1, and we will use the optimal x values
from this table.
From Figure 1, it can be seen that there does not appear to be any variation in the
optimal number of samples to take per subject as the prior variance for the fixed ef-
fects changes. That is, the designs do not change with the prior variance for the fixed
effects, but the values of the utility function decrease as the prior variance increases. It
appears that it is more useful to take a smaller number of samples from a larger number
of individuals to precisely estimate the fixed effects, regardless of how precise our a
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Figure 1: Utility function value versus the number of samples per subject, for a fixed cost of $750, for various
values of the prior variance for the population parameters for: (a) c = 0.1, (b) c = 1, (c) c = 2, (d) c = 10,
and (e) c = 100.
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priori knowledge of these effects is, for a fixed (and somewhat precise) value for the
population variance of the subject-specific effects. This makes sense: since we already
have precise knowledge about the subjects and wish to precisely estimate the popula-
tion parameters, then we should incorporate more subjects into the study (even if they
only have a few samples taken), regardless of our level of knowledge of the popula-
tion parameters. Also, for a precise amount of knowledge of the population parameters
(c = 0.1) there is less variation in the utility values for the different combinations of
the number of samples per subject and number of subjects.
It is important to remember, with respect to our utility function (equation (4)), that
det(X′V−1X + Σ−1σ2) , det(X′V−1X) + det(Σ−1σ2).
This means that varying the prior variance of the fixed effects (cΣ) may slightly affect
the design when the determinant of the posterior precision is taken, where a smaller
value of c will have a larger impact on the design compared to a larger value of c. If
the trace of the posterior precision matrix was taken instead of the determinant, then
varying the prior of the fixed effects would have no impact on the design since the trace
is a linear function.
Now we investigate how changing the population variance of the subject-specific
effects alters the designs: φi ∼ N(0, kΣ), where k = 0.005, 0.05, 0.5, 1, 2, 20. For
the population parameter, we will set the value of c to 10000, to give prior variance
10000Σ, which essentially gives a frequentist analysis. If k ≈ 0, then Var(φi) ≈ 0,
and we will obtain the population parameter frequentist result. We will investigate the
same combinations of the number of subjects and samples per subject as above, and
use the optimal x values from Table 1.
From Figure 2, it can be seen that as the population variance of the subject-specific
effects increases, the optimal number of samples per subject decreases. That is, when
there is a large amount of variation in the values of the subject-specific effects, one
should focus on taking a small number of samples from a larger number of individuals,
so that precise estimates of the population mean parameters can be obtained. If there is
little variation in the subject-specific effects, then one should focus their resources on
taking a larger number of samples from a smaller number of subjects, as there is little
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Figure 2: Utility function value versus the number of samples per subject, for a fixed cost of $750, for various
values of the variance for the subject-specific parameters: (a) k = 0.005, (b) k = 0.05, (c) k = 0.5, (d) k = 1,
(e) k = 2, and (f) k = 20.
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benefit from taking samples from more subjects to precisely estimate the population
means.
An investigation into the sensitivity of the optimal design to the values chosen for
the cost per subject and cost per sample was conducted and is presented in Online
Appendix A. The results from the cost sensitivity analyses supported those of Table
1, in that it is preferable to take a small number of samples from a larger number of
subjects, for this linear mixed effects model and priors.
It is important to note that, although the same fixed total cost is obtained for the
different combinations in Table 1, the total number of observations taken is not the
same for each combination. In Online Appendix B, we assume that the same total
number of observations (here we assume 48) is taken (and that the costs per subject and
sample are equivalent), and investigate the ‘best way’ to divide up these observations.
It was found that the best way to divide up 48 observations was to take 3 samples each
from 16 individuals, so that we could precisely estimate 3 population parameters.
4. Case Study: Population Pharmacokinetics of HEPS in Horses
This case study is concerned with determining the optimal urine sampling times
for a population PK study of the acepromazine (ACP) metabolite 2-(1-hydroxyethyl)
promazine (HEPS) in racing horses. We are also interested in determining the optimal
number of horses to include in the study, and the optimal number of samples to take per
horse (subject to cost constraints). Our case study will be a retrospective study design
which makes use of the data collected and analysed by McGree et al. (2012). We are
interested in re-designing the study to precisely estimate the mean PK parameters of
the population of horses.
In the study conducted by McGree et al. (2012), 30mg of ACP was administered
to 12 horses (geldings) and urine samples were taken at the following times: 2, 4, 6, 8,
12, 24, 36 and 48 hours after administration. The horses were trained to urinate to the
sound of a whistle. Here, we will re-design the urine sampling times from those used
in McGree et al. (2012) so that accurate measures of PK parameters of interest can be
obtained.
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4.1. The model
We assume nd urine samples, t1, t2, ...., tnd , will be collected for n subjects. The
cumulative amount of HEPS in subject i’s urine at the h-th sampling time, Yi,h, is mod-
elled by:
Yi,h = f (φi, th) + i,h, i = 1, ..., n; h = 1, ..., nd,
where
f (φi, th) =
D × FEi (Cli − Vi × ka −Cli × e−kath + Vi × ka × e
−Cli
Vi
th )
Cli − Vi × ka ,
and independent i,h ∼ N(0, σ2add).
Here φi = (logCli, log FEi , logVi) are the PK parameters for the i-th horse. Cl is the
clearance rate, FE is the fraction of HEPS that is excreted renally, and V is the volume
of distribution (a theoretical measure). In this model it is assumed that ka = 35.87 is a
constant (as per McGree et al. (2012)) and D = 30000µg is the drug dose. This model
assumes a first-order absorption and elimination of the drug which is administered
orally. The cumulative amount of the drug in the urine increases over time until all of
the drug is eliminated.
Only additive error, whose variance is given by σ2add, is present in the model. It was
assumed that σ2add ∼ N(1.2 × 104, 3.1 × 106) (based on McGree et al.’s (2012) results).
The priors were obtained from the posterior results of McGree et al. (2012), in
which the Bayesian model above was fitted to the data using MCMC. The population
distribution for the individual parameters φi, i = 1, ..., n, is specified as:
φi ∼ MVN(φ,Ω),
where φ = (logCl, log FE , logV) is the population mean parameter and Ω is the pop-
ulation variance-covariance matrix. Ω is assumed to be known and was obtained from
the results of McGree et al. (2012) and is given by:
Ω =

0.0149 0.0034 −0.0037
0.0034 0.0146 −0.0027
−0.0037 −0.0027 0.0048
 .
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Figure 3: Prior predictive curves of cumulative urine amount of HEPS (online version in colour).
The fixed effects are assumed to have a prior distribution φ ∼ MVN(µ,Σ), with
known mean and variance-covariance matrix:
µ =

6.65
−2.46
8.84
 and Σ =

0.0076 −0.0030 0.0050
−0.0030 0.0050 −0.0030
0.0050 −0.0030 0.0073
 .
The values forΩ and Σ were obtained from the posterior samples which fit the data
for 12 horses and so are very precise.
The estimated posterior densities of φ = (logCl, log FE , logV) that were obtained
by McGree et al. (2012) are displayed in Online Appendix C. These posteriors were
used as our prior for the retrospective design by fitting a multivariate normal distribu-
tion to the MCMC output of McGree et al. (2012). Simulations from the prior pre-
dictive distribution for the cumulative urine amounts of HEPS are displayed in Figure
3.
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No. Subjects No. samples per sub-
ject
Total no. of samples Fixed cost ($)
2 10 20 $3000
3 5 15
4 2 8
3 11 33 $5000
4 7 28
5 5 25
6 3 18
7 2 14
5 15 75 $10 000
8 7 56
12 3 36
Table 2: Different combinations of the number of subjects and the number of samples per subject for various
fixed total costs that were explored for the PK example.
5. Designs for Population PK Study
We now turn our attention to determining the optimal tradeoff between the number
of subjects and samples per subject, and the optimal sampling times for a PK study.
The methods discussed in Section 2 will be applied to the horse PK study introduced
in Section 4. Table 2 displays the combinations of the number of subjects and samples
per subject that are investigated for fixed total costs of $3000, $5000, and $10000.
The utility function is the determinant of the posterior precision of the population
parameters and will be estimated using the procedure described in Section 2.1. We will
implicitly use equation (3) as the cost function, where csub is the cost per horse, and
was set to $500, and csample is the cost per sample, and was set to $100. These values
were determined after consulting several horse PK experts. Separate MCMCs were run
for each of the combinations of the number of horses and number of samples per horse
(i.e., separate MCMCs were run in parallel for each line of Table 2).
5.1. Results
We search for the (near) optimal urine sampling times, which are restricted to oc-
cur between 0 and 48 hours and use the lower dimensional parameterisation discussed
in Section 2. It was assumed that all of the horses were sampled at the same times
following the administration of the drug. The results of the sampling times that were
generated from the (evenly-spaced) percentiles of a Beta(a, b) distribution for the dif-
ferent combinations of the number of subjects and samples per subject are displayed
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in Figure 4. The MCMC convergence diagnostics discussed in Section 2 were satisfied
for all simulations that were performed, and Online Appendix D displays the conver-
gence diagnostics for the MCMC simulations that were performed when n = 3 and
nd = 11 (i.e., the “3 horses, 11 sampling times per horse” combination). The most
computationally intensive component of the MCMC algorithm was the estimation of
the posterior distribution for use in the Bayesian utility function (i.e., Algorithm 2)
since the posterior must be sampled from for each future dataset that is drawn from
the prior predictive distribution. For this example, 100000 samples were required so
that reasonably stable and precise estimates of the utility function could be obtained
via importance sampling.
For each of the total fixed costs considered, it was found that it was preferable to
heavily sample a smaller number of subjects (see Figure 4). That is, if one is interested
in obtaining precise posterior distributions of the population (urine) PK parameters,
then one should heavily sample (10-15 samples per individual) a small number, say
2-5, of individuals. From Figure 4, it can be seen that the more subjects included and
samples taken in the study the better, as expected, provided there is no upper limit to
the cost of the study (which would be rare in practice). However, these designs may
not be suitable in practice as it may be difficult or unethical to take a large number,
say, 15 urine samples from an individual within 48 hours. It should be noted that these
conclusions are subject to the cost ratios used in this study.
Our results are in agreement with Jonsson et al. (1996), but are in contrast to the
results obtained by Sheiner and Beal (1983), and Hashimoto and Sheiner (1991), who
recommend that designs that use a larger number of subjects that are sparsely sampled
are preferable over designs that use a smaller number of individuals that are heavily
sampled. However, their designs are not fully Bayesian and have different design ob-
jectives to those considered in this paper. Also, these studies only consider up to three
sampling times, which are fixed in their values, and do not optimise the sampling times
over the design space as we have done here. These results highlight the fact that the
optimal sampling strategy may not be obvious and optimisation of the design problem
is required using the methods we have described.
The (near) optimal sampling times were evenly spread across the design space (see
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1.46 (1.46, 1.46) x 1010
a = 0.4, b = 0.5           
1.46 (1.46, 1.47) x 1010
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1.47 (1.47,   1.48) x 1010
a=0.5, b = 0.6               
1.48 (1.47, 1.48) x 1010
a = 0.3, b = 0.4           
1.49 (1.48, 1.51) x 1010
a = 0.4, b = 0.5           
7 horses, 2 sampling times
6 horses, 3 sampling times
5 horses, 5 sampling times
4 horses, 7 sampling times
3 horses, 11 sampling times
(c)
0 5 10 15 20 25 30 35 40 45 50
Sampling times (hours)
 
 
1.49 (1.49, 1.50) x 1010
a = 0.6, b = 0.7           
1.52 (1.50, 154) x 1010 
a = 0.7, b = 0.7           
1.54 (1.51, 1.56) x 1010
a = 0.7, b = 0.8           
12 horses, 3 sampling times
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5 horses, 15 sampling times
Figure 4: PK sampling times generated by the evenly spaced percentiles of a Beta(a, b) distribution, for the
various combinations of the number of horses and number of sampling times per horse, for a fixed cost of (a)
$3000, (b) $5000, and (c)$10000. The utility function values are displayed next to the sampling times, along
with the values for the shape parameters for the beta distribution that was used to generate the sampling
times.
23
Figure 4). For a small number of sampling times, preference was given to sampling
times that spanned the central region of the design space (e.g., 10 - 40 hours, Figure
4). This is the region of the PK curve where the increase in the cumulative amount
of HEPS in urine begins to progress at a slower rate and eventually asymptotes (see
Figure 3). As the number of sampling times increased, they were evenly spread out
from the central region of the design space to cover a greater region of the PK curve.
The earliest and latest sampling times occurred at 0.12 and 47.4 hours respectively, and
were associated with the 5 horses, 15 sampling times combination. These sampling
times covered the majority of the design space [0, 48] hours. For the majority of the
population designs (where more than 3 samples were taken), sampling continued after
the cumulative amount of drug had reached an asymptote.
It should be noted that there was little difference in the utility function values for the
different combinations of the number of subjects and samples per subject, for a fixed
total cost. In Figure 4(a) the utility function values ranged from 1.44 to 1.46, in Figure
4(b) they ranged from 1.46 to 1.49, and ranged from 1.49 to 1.54 in Figure 4(c) (on
average). Therefore it is difficult to make strong statements on the optimal sampling
strategies, based on these results. Alternative priors for the fixed effects or models for
the random effects may produce utility surfaces that are less flat.
We also tried implementing Algorithm 1 to search for the optimal number of sub-
jects, number of samples per subject, and sampling times all at once, but this was found
to be too computationally intensive.
A prior sensitivity study was also conducted (in a similar fashion to Section 3.1)
and can be found in Online Appendix E. It was found that the designs did not vary when
the prior variance for the population parameters was altered (similar to Figure 1), and
it was most useful to heavily sample a smaller number of subjects. When the variation
between the subjects (population variance) was small, it was preferable to take more
samples from a smaller number of individuals, as there was little benefit from sampling
a larger number of individuals. When the variation between the subjects was larger, it
was preferable to take a smaller number of samples from more subjects, so that precise
posterior distributions of the population parameters can be obtained. This is similar to
Figure 2.
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6. Discussion
In this article we have discussed and presented methods that can be used to find
optimal fully Bayesian designs for mixed effects models, for both linear and non-linear
models. The design problem was to determine the optimal number of subjects, the
optimal number of samples per subject and the optimal predictor variable values (as in
the linear model example) or the near optimal sampling times for a PK study (nonlin-
ear example), to precisely estimate the model parameter of interest, subject to a cost
constraint. Whilst the computational methods used in this work are not novel, their
adaptation and application to find fully Bayesian static optimal designs for NLMEMs
are new. Searches over a number of different design variables (some of which had a
continuous design space) were performed, which also has not been previously imple-
mented to find fully Bayesian static designs for NLMEMs.
Population designs comprise of a set of elementary designs that are to be carried
out on groups of subjects. The elementary designs consist of several values of the de-
sign variable (e.g., blood sampling times, treatment doses etc) that are to be performed
on each subject belonging to the design. The number of samples to be taken and the
values of the design variable may differ between subjects within an elementary design,
and between the elementary designs. For simplicity, we assumed that all individuals
in the examples considered in this paper had the same number of measurements taken
and were sampled at the same experimental design. Previous simulation population PK
studies (e.g., Sheiner and Beal (1983); Jonsson et al. (1996)) have found that the preci-
sion and accuracy of the parameter estimates are affected by the number of elementary
designs, the number of subjects per elementary design, and the number and allocation
of the design points (e.g., sampling times). Therefore, our design set up (in terms of
having one elementary design) may not be optimal for population studies and future
studies may wish to investigate the use of different elementary designs for different
groups of subjects. This is likely to be very computationally intensive as many design
variables would be involved.
In both the linear and nonlinear examples, we were also interested in determining
the optimal number of subjects and samples per subject, subject to a cost constraint.
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This was achieved by searching over several different combinations of the number of
subjects and samples per subject that resulted in the same total fixed cost. We had
adapted the Mu¨ller (1999) algorithm to treat the number of subjects and the number of
samples per subject as design variables, so that the optimal number of subjects, samples
per subject and sampling times could be found simultaneously. However, one cannot
search over a large number of design variables using the Mu¨ller (1999) algorithm as
it becomes too computationally intensive to search over the joint space (d, θ, y) and to
determine the multivariate mode for the large number of design variables.
The results obtained in this study are dependent on the cost constraints and prior
distributions used for the design problems, and for both examples, it is likely that differ-
ent sampling strategies would have been achieved if different cost constraints or prior
distributions were used. For the linear mixed effects model that was considered in this
work, it was found that it was more useful to take a small number of samples from a
larger number of individuals if one is interested in obtaining precise posterior distri-
butions of the population parameters. For the NLMEM example (PK study), it was
found that it was preferable to heavily sample a smaller number of individuals, so that
precise posterior distributions of the population PK parameters could be obtained. The
differences in the optimal sampling strategies between the two examples considered
highlights how problem-dependent optimal Bayesian designs for mixed effects models
are, emphasising the need for the optimisation methods presented in this paper.
A lower dimensional parameterisation was used to reduce the computational bur-
den of searching over a large number of design points. The MCMC algorithm searched
over the two design variables (a, b), and once these optimal values are found, the design
points were generated from the evenly-spaced percentiles of the Beta(a, b) distribution,
scaled to [0, 48] hours. We have previously found the beta proposal scheme to be quite
flexible in generating designs, in that a wide variety of designs can be generated from
this scheme depending on the values of the shape parameters used (Ryan et al. (2014)).
This parameterisation could be extended to offer further flexibility by including another
design variable that determines the optimal percentiles of the beta distribution to use.
It must be stressed that the designs generated by these lower dimensional parameteri-
sations are not optimal but near optimal.
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In the examples considered in this paper, we were able to estimate the posterior
density (for use in the Bayesian utility functions) analytically, or via importance sam-
pling. Future studies that design for mixed effects models in a Bayesian framework
should investigate alternative methods for estimating the posterior density, such as
adaptive Gaussian quadrature (e.g., Rabe-Hesketh et al. (2004)) or Laplace approxi-
mations (e.g., Wolfinger (1993)), which may prove to be computationally faster and
more efficient. We found that importance sampling from the prior (fixed effects) and
population distribution (random effects) was somewhat computationally intensive as
many importance samples (Mp = 100000) were required to obtain reasonably stable
(based on the ESS) and precise estimates of the utility function.
Supplementary Materials
Online Appendices that are referenced in Sections 3, 4 and 5 are available with this
paper at the CSDA website on the ScienceDirect Online Library.
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